Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.61 USD | +0.71% | +0.97% | +45.89% |
05-02 | Immunome, Inc. Appoints Kinney Horn as Chief Business Officer | CI |
04-30 | JPMorgan Starts Immunome With Overweight Rating, $24 Price Target | MT |
Sales 2024 * | 9.6M 13.13M | Sales 2025 * | 3.2M 4.38M | Capitalization | 936M 1.28B |
---|---|---|---|---|---|
Net income 2024 * | -104M -142M | Net income 2025 * | -144M -197M | EV / Sales 2024 * | 97.5 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 292 x |
P/E ratio 2024 * |
-8.64
x | P/E ratio 2025 * |
-6.94
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.08% |
1 day | +0.71% | ||
1 week | +0.97% | ||
Current month | +11.02% | ||
1 month | -24.15% | ||
3 months | -30.28% | ||
6 months | +89.44% | ||
Current year | +45.89% |
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-10-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 01-01 |
Director/Board Member | 70 | 11-06 | |
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 15.61 | +0.71% | 832,567 |
24-05-10 | 15.5 | +0.13% | 1,046,784 |
24-05-09 | 15.48 | -1.40% | 344,517 |
24-05-08 | 15.7 | +2.41% | 505,028 |
24-05-07 | 15.33 | -0.84% | 342,932 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.89% | 929M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- IMNM Stock